<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>VITARNA&#039;s Progress in Targeting Age-Related Mutations  - Hex Index</title>
  <link rel="stylesheet" href="../../styles.css">
</head>
<body class="reading-mode">
  <header class="reading-header">
    <a href="../../index.html" class="back-link">&larr; Back to Library</a>
  </header>
  <main class="reading-content">
    
    <article class="article-page">
      <header class="article-header">
        <h1>VITARNA&#039;s Progress in Targeting Age-Related Mutations </h1>
        <div class="article-meta">
          <span class="author">By VitaDAO</span>
          <span class="separator">&middot;</span>
          <a href="../../publication/vitadao/index.html" class="publication">
            VitaDAO Newsletter
          </a>
          <span class="separator">&middot;</span><time>Sep 6, 2024</time>
          <span class="separator">&middot;</span>
          <span class="read-time">2 min read</span>
        </div>
      </header>

      

      <div class="article-excerpt">
        <div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!2Anq!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcf971d81-17b6-4109-9b0d-fabf2903866e_1991x1134.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!2Anq!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcf971d81-17b6-4109-9b0d-fabf2903866e_1991x1134.png 424w, https://substackcdn.com/image/fetch/$s_!2Anq!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcf971d81-17b6-4109-9b0d-fabf2903866e_1991x1134.png 848w, https://substackcdn.com/image/fetch/$s_!2Anq!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcf971d81-17b6-4109-9b0d-fabf2903866e_1991x1134.png 1272w, https://substackcdn.com/image/fetch/$s_!2Anq!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcf971d81-17b6-4109-9b0d-fabf2903866e_1991x1134.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!2Anq!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcf971d81-17b6-4109-9b0d-fabf2903866e_1991x1134.png" width="1456" height="829" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/cf971d81-17b6-4109-9b0d-fabf2903866e_1991x1134.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:829,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:729048,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!2Anq!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcf971d81-17b6-4109-9b0d-fabf2903866e_1991x1134.png 424w, https://substackcdn.com/image/fetch/$s_!2Anq!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcf971d81-17b6-4109-9b0d-fabf2903866e_1991x1134.png 848w, https://substackcdn.com/image/fetch/$s_!2Anq!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcf971d81-17b6-4109-9b0d-fabf2903866e_1991x1134.png 1272w, https://substackcdn.com/image/fetch/$s_!2Anq!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcf971d81-17b6-4109-9b0d-fabf2903866e_1991x1134.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"></div></div></div></a></figure></div><p>In a recent data drop on July 26, 2024, <a href="https://www.youtube.com/watch?v=i_J21t8eR8E">Artan Bio shared</a> significant progress in its innovative approach to combating genetic diseases and aging. Funded by VitaDAO ($91k) as an IP-NFT and raising over $300k through the tokenization of the Artan Bio IP-NFT, the biotech startup is developing tRNA suppressors targeting nonsense mutations linked to these conditions.</p><p>Led by CEO<strong> Anthony Schwartz</strong> and CSO <strong>Michael Torres</strong>, Artan Bio focuses on arginine mutations, specifically the CGA codon, common in proteins related to DNA damage, neurodegeneration, and tumor suppressors. Their approach aims to restore protein levels of these age-related proteins.</p><p>Initial funding enabled the development of a protein-based screening assay, leading to the design and testing of 15 potential drug candidates. Upon further testing, at least two potential lead drug candidates showed promise in correcting nonsense mutations in cells via the screening assay.</p><p>Currently, VitaRNA by Artan Bio is producing viral vectors for animal studies using AAV9, an FDA-approved gene delivery system known for its broad tissue tropism. Next steps include:</p><p>1. Generating and characterizing the AAV9 virus with lead drug candidates</p><p>2. Validating vector efficacy in delivering gene therapy and correcting nonsense mutations</p><p>3. Conducting in vivo safety and efficacy studies</p><p>4. Engaging with IP attorneys for patent strategy and filing the necessary patent applications</p><p>5. Consulting regulatory experts on clinical trial planning</p><p>The company received an update on 09/05/2024 from the contract research lab performing the experiments as mentioned above. The initial draft report clearly demonstrated that their lead candidates are active and can be packaged in a gene therapy vector. The company plans for its next funding proposal within one month to support the scale-up of the candidates for use in animal efficacy and safety studies. As Artan Bio progresses, it emphasizes community engagement while considering future funding options.</p><p>This work could open new avenues in treating genetic diseases and addressing fundamental causes of aging, promising a healthier future for all.</p><p>To watch the full data drop presentation from VitaRNA by Artan Bio, visit:</p><div id="youtube2-i_J21t8eR8E" class="youtube-wrap" data-attrs="{&quot;videoId&quot;:&quot;i_J21t8eR8E&quot;,&quot;startTime&quot;:null,&quot;endTime&quot;:null}" data-component-name="Youtube2ToDOM"><div class="youtube-inner"><iframe src="https://www.youtube-nocookie.com/embed/i_J21t8eR8E?rel=0&amp;autoplay=0&amp;showinfo=0&amp;enablejsapi=0" frameborder="0" loading="lazy" gesture="media" allow="autoplay; fullscreen" allowautoplay="true" allowfullscreen="true" width="728" height="409"></iframe></div></div><p>Learn more: &nbsp;<a href="https://vitarna.xyz">http://vitarna.xyz</a></p><p>Join the community: <a href="https://t.co/D0rPr5Csdc">&nbsp;</a><a href="http://t.me/vitarna">http://t.me/vitarna</a></p><p>Coingecko:<a href="https://www.coingecko.com/en/coins/vitarna"> https://www.coingecko.com/en/coins/vitarna</a></p></source>
      </div>

      <div class="read-full-article">
        <a href="https://vitadao.substack.com/p/vitarnas-progress-in-targeting-age" class="read-button" target="_blank" rel="noopener">
          Read full article on VitaDAO Newsletter &rarr;
        </a>
        <p class="copyright-note">
          This excerpt is provided for preview purposes.
          Full article content is available on the original publication.
        </p>
      </div>
    </article>
  
  </main>
</body>
</html>